α-突触核蛋白寡聚体与神经丝轻链预测纯自主神经衰竭的表型转化
研究纳入32例纯自主神经衰竭(PAF)患者,随访中位3.9年,检测基线脑脊液αSyn寡聚体(PMCA法)和NfL(ELISA法)。基线NfL仅在未来转化为多系统萎缩(MSA)的患者中升高,能完美区分未来MSA与PD/DLB转化者及未转化者;αSyn-PMCA几乎均阳性,其反应幅度和动力学可预测MSA转化。
要点
- 基线脑脊液NfL升高仅见于未来转化为MSA的PAF患者。
- αSyn-PMCA在PAF脑脊液中几乎均阳性,支持其为α-突触核蛋白病。
- PMCA反应幅度和动力学可预测PAF向MSA转化。
核心结论
- αSyn-PMCA在PAF脑脊液中几乎均阳性,确立PAF为α-突触核蛋白病。
- NfL及αSyn PMCA的幅度和反应动力学能可靠预测哪些PAF患者最终转化为MSA。
研究设计与样本
- 前瞻性队列研究,纳入32例经充分表征的PAF患者,2016年6月至2019年2月于Mayo Clinic Rochester入组,每年随访以确定向MSA、PD或DLB的表型转化。
- 基线脑脊液用ELISA测NfL,用蛋白错误折叠循环扩增(PMCA)检测αSyn寡聚体。
主要发现
- 患者随访中位3.9年,5例转化为MSA,2例转化为PD,2例转化为DLB。
- 基线NfL仅在未来发生MSA的患者中升高,完美区分未来MSA转化者与未来PD/DLB转化者及未转化者。
- αSyn-PMCA除2例外(94%)均为阳性;5份样本的PMCA反应表现为最大荧光和反应动力学,与既往描述的MSA患者显著不同,这些患者后来均发生MSA。
临床怎么用
- 对PAF患者,基线脑脊液NfL和αSyn-PMCA可用于预后判断,预测未来向MSA转化。
- 有助于在运动症状出现前区分MSA与路易体突触核蛋白病,为疾病修饰疗法试验提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore the role of alpha-synuclein (αSyn) oligomers and neurofilament light chain (NfL) in cerebrospinal fluid (CSF) of patients with pure autonomic failure (PAF) as markers of future phenoconversion to multiple system atrophy (MSA). METHODS: Well-characterized patients with PAF (n = 32) were enrolled between June 2016 and February 2019 at Mayo Clinic Rochester and followed prospectively with annual visits to determine future phenoconversion to MSA, Parkinson's disease (PD), or dementia with Lewy bodies (DLB). ELISA was utilized to measure NfL and protein misfolding cyclic amplification (PMCA) to detect αSyn oligomers in CSF collected at baseline. RESULTS: Patients were followed for a median of 3.9 years. Five patients converted to MSA, 2 to PD, and 2 to DLB. NfL at baseline was elevated only in patients who later developed MSA, perfectly separating those from future PD and DLB converters as well as non-converters. ASyn-PMCA was positive in all but two cases (94%). The PMCA reaction was markedly different in five samples with maximum fluorescence and reaction kinetics previously described in MSA patients; all of these patients later developed MSA. INTERPRETATION: αSyn-PMCA is almost invariably positive in the CSF of patients with PAF establishing this condition as α-synucleinopathy. Both NfL and the magnitude and reaction kinetics of αSyn PMCA faithfully predict which PAF patients will eventually phenoconvert to MSA. This finding has important implications not only for prognostication, but also for future trials of disease modifying therapies, allowing for differentiation of MSA from Lewy body synucleinopathies before motor symptoms develop. ANN NEUROL 2021;89:1212-1220.
引用
- Singer W, Schmeichel AM, Shahnawaz M, et al. Alpha-Synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure. Ann Neurol. 2021. PMID: 33881777. doi:10.1002/ana.26089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。